nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2019-23-2-18-40nefr-1675Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК И АРИТМИИ: ИТОГИ КОНФЕРЕНЦИИ KDIGO ПО СПОРНЫМ ВОПРОСАМCHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCEТурахияМинту П.TurakhiaMintu P.mintu@stanford.eduБланкештинПетер Дж.BlankestijnPeter J.

отделение нефрологии

Department of Nephrology,room F03.220

КаррероХуан-ХесусCarreroJuan-Jesus

отделение медицинской эпидемиологии и биостатистики

Department of Medical Epidemiology and Biostatistics

КлазеКатерин М.ClaseCatherine M.

отделение Медицины и отделение научных методов исследования в медицине

ДеоРайатDeoRajat

секция электрофизиологии, отделение сердечно-сосудистой медицины

ГерцогЧарльз А.HerzogCharles A.КаснерСкотт Е.KasnerScott E.

отделение неврологии

ПассамРод С.PassmanRod S.Пекуа-ФийоРобертоPecoits-FilhoRobertoРайнекеХолгерReineckeHolger

отделение кардиологии и ангиологии

ШроффГаутам Р.ShrofGautam R.

отделение кардиологии

ЗаребаВойцехZarebaWojciechЧеунгМайклCheungMichaelВилерДэвид К.WheelerDavid C.ВаннерКристофWannerChristophВинкельмайерВольфганг К.WinkelmayerWolfgang C.Университетская медицинская школа Стэндфорда, г. Пало АльтоСоединённые Штаты АмерикиStanford University School of Medicine, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave, 111C, Palo Alto, CA 94304United StatesУниверситетского медицинского центра, г. Утрехт, НидерландыНидерландыUniversity Medical Center, P.O. Box 85500, 3508GA UtrechtNetherlandsКаролинский Институт, г. СтокгольмШвецияKarolinska Institutet,Nobels va¨g 12A, Box 281, 171 77 StockholmSwedenУниверситет МакмастераКанадаDepartment of Medicine and Department of Health Research Methods, Evidence, and Impact, McMaster University, St.Joseph’s Healthcare, Marian Wing, 3rd Floor, M333, 50 Charlton Ave. E, Hamilton, Ontario L8N 4A6CanadaШкола медицины Перельмана Университета ПенсильванииСоединённые Штаты АмерикиSection of Electrophysiology, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce Street, 9 Founders Cardiology, Philadelphia, 19104 PAUnited Statesотдел кардиологии, отделение медицины Медицинского центра округа Хеннипин и Университета Миннесоты, Миннеаполис, Миннесота и Группа по изучению хронических заболеваний, Научный медицинский фонд МиннеаполисаСоединённые Штаты АмерикиDivision of Cardiology,Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota and Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 S. 8th Street, S4.100, Minneapolis, 55404 MNUnited Statesбольница Университета Пенсильвании, ФиладельфияСоединённые Штаты АмерикиDepartment of Neurology, 3W Gates Bldg. Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, 19104-4283 PAUnited StatesМедицинская школа Северо-Западного университета имени Файнберга и Седечной-сосудистый институт Блума, г. ЧикагоСоединённые Штаты АмерикиNorthwestern University Feinberg School of Medicine and the Bluhm Cardiovascular Institute, 201 E. Huron St. Chicago, 60611 IL, USAUnited StatesШкола медицины, Папский католический университет Параны, КуритибаБразилияSchool of Medicine, Pontificia Universidade Catolica do Paraná, Rua Imaculada Conceic¸~ao 1155, 80220-901 Curitiba PRBrazilУниверситетская клиника Мюнстера, МюнстерГерманияDepartment für Kardiologie und Angiologie Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 MuensterGermanyМедицинский центр округа Хеннипин, МиннеаполисСоединённые Штаты АмерикиDivision of Cardiology, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, 55415 MNUnited StatesПрограмма по изучению сердца, Университет Медицинского центра Рочестера, РочестерСоединённые Штаты АмерикиHeart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, Saunders Research Building, 265 Crittenden Blvd. CU 420653, Rochester, 14642 NYUnited StatesОфис Kdigo, БрюссельБельгияKDIGO, Avenue Louise 65, Suite 11, 1050 BrusselsBelgiumЦентр нефрологии, Университетский колледж Лондона, ЛондонВеликобританияCentre for Nephrology, University College London,Rowland Hill Street, London NW3 2PF, UKUnited Kingdomотдел нефрологии, отделение медицины, Университетская клиника Вюрцбурга, г. ВюрцбургГерманияDivision of Nephrology, Department of Medicine, University Hospital of Würzburg, Oberduerrbacherstr. 6 Würzburg D-97080GermanyИнститут здоровья почек Зельцмана, секция нефрологии, отделение медицины, колледж медицины Бэйлора, ХьюстонСоединённые Штаты АмерикиSelzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, ABBR R705, MS: 395, Houston, 77030-3411 TXUnited States2019200220192321840Copyright © Турахия М.П., Бланкештин П.Д., Карреро Х., Клазе К.М., Део Р., Герцог Ч.А., Каснер С.Е., Пассам Р.С., Пекуа-Фийо Р., Райнеке Х., Шрофф Г.Р., Зареба В., Чеунг М., Вилер Д.К., Ваннер К., Винкельмайер В.К., 20192019Турахия М.П., Бланкештин П.Д., Карреро Х., Клазе К.М., Део Р., Герцог Ч.А., Каснер С.Е., Пассам Р.С., Пекуа-Фийо Р., Райнеке Х., Шрофф Г.Р., Зареба В., Чеунг М., Вилер Д.К., Ваннер К., Винкельмайер В.К.Turakhia M.P., Blankestijn P.J., Carrero J., Clase C.M., Deo R., Herzog C.A., Kasner S.E., Passman R.S., Pecoits-Filho R., Reinecke H., Shrof G.R., Zareba W., Cheung M., Wheeler D.C., Wanner C., Winkelmayer W.C.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1675

Пациенты, страдающие хронической болезнью почек (ХБП), имеют предрасположенность к развитию таких нарушений ритма, как фибрилляция предсердий (ФП)/ трепетание предсердий, наджелудочковая тахикардия и внезапная сердечная смерть (ВСС). Несмотря на то, что существуют разнообразные терапевтические возможности, включая лекарственное лечение, использование приборов и применение других мероприятий, их использование при ХБП остается затруднительным и ограниченным. Пациентов с ХБП, в том числе с терминальной почечной недостаточностью, обычно не включают в рандомизированные исследования по лечебным стратегиям при аритмиях, хотя эта ситуация в настоящее время претерпевает изменения. Консенсус сердечно-сосудистого общества кардиологов не так давно выявил этот пробел в лечении пациентов с ХБП и нарушениями сердечного ритма. С целью установления основных аспектов, относящихся к наилучшему предотвращению, оптимальному ведению таких больных и лечению аритмий и их осложнений, группа Kidney Disease: Improving Global Outcomes (KDIGO) провела международную мультидисциплинарную конференцию «ХБП и аритмии» в Берлине, Германия, в октябре 2016 г.

Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders, including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular arrhythmias, and sudden cardiac death (SCD). While treatment options, including drug, device, and procedural therapies, are available, their use in the setting of CKD is complex and limited. Patients with CKD and end-stage kidney disease have historically been under-represented or excluded from randomized trials of arrhythmia treatment strategies, 1 although this situation is changing. Cardiovascular society consensus documents have recently identified evidence gaps for treating patients with CKD and heart rhythm disorders. To identify key issues relevant to the optimal prevention, management, and treatment of arrhythmias and their complications in patients with kidney disease, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference in Berlin, Germany, titled CKD and Arrhythmias in October 2016.

хроническая болезнь почекаритмиифибрилляция предсердийпероральные антикоагулянтыchronic kidney diseasearrhythmiasatrial fibrillationoral anticoagulantsReferencesCharytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021–2030. Doi: https://Doi.org/10.1038/ sj.ki.5001934Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021–2030. Doi: https://Doi.org/10.1038/ sj.ki.5001934Konstantinidis I, Nadkarni GN, Yacoub R et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016;176: 121–124. Doi: https://Doi.org/10.1001/jamainternmed.2015.6102Konstantinidis I, Nadkarni GN, Yacoub R et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016;176: 121–124. Doi: https://Doi.org/10.1001/jamainternmed.2015.6102Boriani G, Savelieva I, Dan GA et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015;17: 1169–1196. Doi: https://Doi. org/10.1093/europace/euv202Boriani G, Savelieva I, Dan GA et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015;17: 1169–1196. Doi: https://Doi. org/10.1093/europace/euv202Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17: 1467–1507. Doi: https://Doi. org/10.1093/europace/euv309Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17: 1467–1507. Doi: https://Doi. org/10.1093/europace/euv309Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962. Doi: https://Doi. org/10.1093/ejcts/ezw313Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962. Doi: https://Doi. org/10.1093/ejcts/ezw313Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381. Doi: https://Doi. org/10.1093/eurheartj/ehw106Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381. Doi: https://Doi. org/10.1093/eurheartj/ehw106Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the. European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867. Doi: https://Doi.org/10.1714/2174.23496Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the. European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867. Doi: https://Doi.org/10.1714/2174.23496Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129: 837–847. Doi: https://Doi. org/10.1161/CIRCULATIONAHA.113.005119Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129: 837–847. Doi: https://Doi. org/10.1161/CIRCULATIONAHA.113.005119Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158–169. Doi: https://Doi.org/10.1016/S0140-6736(13)60439-0Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158–169. Doi: https://Doi.org/10.1016/S0140-6736(13)60439-0Soliman EZ, Prineas RJ, Go AS, Xie D et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102–1107. Doi: https://Doi.org/10.1016/j.ahj.2010.03.027Soliman EZ, Prineas RJ, Go AS, Xie D et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102–1107. Doi: https://Doi.org/10.1016/j.ahj.2010.03.027Ananthapanyasut W, Napan S, Rudolph EH et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5: 173–181. Doi: https://Doi.org/10.2215/CJN.03170509Ananthapanyasut W, Napan S, Rudolph EH et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5: 173–181. Doi: https://Doi.org/10.2215/CJN.03170509McManus DD, Corteville DC, Shlipak MG et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol 2009;104:1551–1555. Doi: https://Doi.org/10.1016/j.amjcard.2009.07.026McManus DD, Corteville DC, Shlipak MG et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol 2009;104:1551–1555. Doi: https://Doi.org/10.1016/j.amjcard.2009.07.026Zimmerman D, Sood MM, Rigatto C et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27: 3816–3822. Doi: https://Doi.org/10.1093/ndt/gfs416Zimmerman D, Sood MM, Rigatto C et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27: 3816–3822. Doi: https://Doi.org/10.1093/ndt/gfs416Wetmore JB, Mahnken JD, Rigler SK et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/ Medicaid-eligible dialysis patients. Kidney Int 2012; 81:469–476. Doi: https://Doi.org/10.1038/ki.2011.416Wetmore JB, Mahnken JD, Rigler SK et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/ Medicaid-eligible dialysis patients. Kidney Int 2012; 81:469–476. Doi: https://Doi.org/10.1038/ki.2011.416Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of longterm hemodialysis patients. Am J Kidney Dis 2005;46:897–902. Doi: https:// Doi.org/10.1053/j.ajkd.2005.07.044Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of longterm hemodialysis patients. Am J Kidney Dis 2005;46:897–902. Doi: https:// Doi.org/10.1053/j.ajkd.2005.07.044Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77: 1098–1106. Doi: https:// Doi.org/10.1038/ki.2009.477Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77: 1098–1106. Doi: https:// Doi.org/10.1038/ki.2009.477Roy-Chaudhury P, Williamson DE, Tumlin JA, Charytan DM, Prakash K, Kher VK. Arrhythmic risk in patients with type II diabetes on hemodialysis: preliminary results from the Monitoring in Dialysis (MiD) Clinical Study. Abstract THPO805. J Am Soc Nephrol 2015;26:275ARoy-Chaudhury P, Williamson DE, Tumlin JA, Charytan DM, Prakash K, Kher VK. Arrhythmic risk in patients with type II diabetes on hemodialysis: preliminary results from the Monitoring in Dialysis (MiD) Clinical Study. Abstract THPO805. J Am Soc Nephrol 2015;26:275AKonigsbrugge O, Posch F, Antlanger M et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDI-alysis (VIVALDI). PLoS One 2017;12:e0169400. Doi: https://Doi. org/10.1371/journal.pone.0169400Konigsbrugge O, Posch F, Antlanger M et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDI-alysis (VIVALDI). PLoS One 2017;12:e0169400. Doi: https://Doi. org/10.1371/journal.pone.0169400Alonso A, Lopez FL, Matsushita K et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946–2953. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.111.020982Alonso A, Lopez FL, Matsushita K et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946–2953. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.111.020982Sandhu RK, Kurth T, Conen D et al. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol 2012; 109:538–542. Doi: https://Doi.org/10.1016/j.amjcard.2011.10.006Sandhu RK, Kurth T, Conen D et al. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol 2012; 109:538–542. Doi: https://Doi.org/10.1016/j.amjcard.2011.10.006Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:629– 636. Doi: https://Doi.org/10.1016/j.ahj.2009.06.031Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:629– 636. Doi: https://Doi.org/10.1016/j.ahj.2009.06.031Horio T, Iwashima Y, Kamide K et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010;28:1738–1744. Doi: https://Doi.org/10.1097/HJH.0b013e32833a7dfeHorio T, Iwashima Y, Kamide K et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010;28:1738–1744. Doi: https://Doi.org/10.1097/HJH.0b013e32833a7dfeShang W, Li L, Huang S et al. Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. PLoS One 2016;11:e0155581. Doi: https://Doi.org/10.1371/journal.pone.0155581Shang W, Li L, Huang S et al. Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. PLoS One 2016;11:e0155581. Doi: https://Doi.org/10.1371/journal.pone.0155581Alonso A, Krijthe BP, Aspelund T et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013;2:e000102. Doi: https://Doi.org/10.1161/JAHA.112.000102Alonso A, Krijthe BP, Aspelund T et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013;2:e000102. Doi: https://Doi.org/10.1161/JAHA.112.000102Deo R, Katz R, Kestenbaum B et al. Impaired kidney function and atrial fibrillation in elderly subjects. J Card Fail 2010;16:55–60. Doi: https://Doi.org/10.1016/j.cardfail.2009.07.002Deo R, Katz R, Kestenbaum B et al. Impaired kidney function and atrial fibrillation in elderly subjects. J Card Fail 2010;16:55–60. Doi: https://Doi.org/10.1016/j.cardfail.2009.07.002Liao JN, Chao TF, Liu CJ et al. Incidence and risk factors for newonset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 2015;87:1209–1215. Doi: https://Doi.org/10.1038/ki.2014.393Liao JN, Chao TF, Liu CJ et al. Incidence and risk factors for newonset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 2015;87:1209–1215. Doi: https://Doi.org/10.1038/ki.2014.393Goldstein BA, Arce CM, Hlatky MA et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012;126:2293–2301. Doi: https:// Doi.org/10.1161/CIRCULATIONAHA.112.099606Goldstein BA, Arce CM, Hlatky MA et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012;126:2293–2301. Doi: https:// Doi.org/10.1161/CIRCULATIONAHA.112.099606Winkelmayer WC, Patrick AR, Liu J et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011;22:349–357. Doi: https://Doi.org/10.1681/ ASN.2010050459Winkelmayer WC, Patrick AR, Liu J et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011;22:349–357. Doi: https://Doi.org/10.1681/ ASN.2010050459Providência R, Marijon E, Boveda S et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 2014;114:646–653. Doi: https://Doi.org/10.1016/j. amjcard.2014.05.048Providência R, Marijon E, Boveda S et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 2014;114:646–653. Doi: https://Doi.org/10.1016/j. amjcard.2014.05.048Piccini JP, Stevens SR, Chang Y et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224– 232. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.112.107128Piccini JP, Stevens SR, Chang Y et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224– 232. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.112.107128Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625–635. Doi: https://Doi.org/10.1056/NEJMoa1105594Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625–635. Doi: https://Doi.org/10.1056/NEJMoa1105594Go AS, Fang MC, Udaltsova N et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363–1369. Doi: https://Doi. org/10.1161/CIRCULATIONAHA.108.816082Go AS, Fang MC, Udaltsova N et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363–1369. Doi: https://Doi. org/10.1161/CIRCULATIONAHA.108.816082Wetmore JB, Ellerbeck EF, Mahnken JD et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann Epidemiol 2013;23:112–118. Doi: https://Doi.org/10.1016/j.annepidem.2012.12.011Wetmore JB, Ellerbeck EF, Mahnken JD et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann Epidemiol 2013;23:112–118. Doi: https://Doi.org/10.1016/j.annepidem.2012.12.011Conen D, Chae CU, Glynn RJ et al. Risk of death and cardiovascular events in initially healthy women with newonset atrial fibrillation. JAMA 2011;305:2080–2087. Doi: https://Doi. org/10.1001/jama.2011.659Conen D, Chae CU, Glynn RJ et al. Risk of death and cardiovascular events in initially healthy women with newonset atrial fibrillation. JAMA 2011;305:2080–2087. Doi: https://Doi. org/10.1001/jama.2011.659Shih CJ, Ou SM, Chao PW et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 2016;133:265–272. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.115.018294Shih CJ, Ou SM, Chao PW et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 2016;133:265–272. Doi: https://Doi.org/10.1161/CIRCULATIONAHA.115.018294Lenihan CR, Montez-Rath ME, Scandling JD et al. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant 2013;13:1566–1575. Doi: https://Doi.org/10.1111/ajt.12197Lenihan CR, Montez-Rath ME, Scandling JD et al. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant 2013;13:1566–1575. Doi: https://Doi.org/10.1111/ajt.12197Findlay MD, Thomson PC, MacIsaac R et al. Risk factors and outcome of stroke in renal transplant recipients. Clin Transplant 2016; 30: 918–924. Doi: 10.1111/ctr.12765Findlay MD, Thomson PC, MacIsaac R et al. Risk factors and outcome of stroke in renal transplant recipients. Clin Transplant 2016; 30: 918–924. Doi: 10.1111/ctr.12765Bansal N, Xie D, Tao K et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016; 11: 1189–1196. Doi: 10.2215/CJN.10921015Bansal N, Xie D, Tao K et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016; 11: 1189–1196. Doi: 10.2215/CJN.10921015Bansal N, Fan D, Hsu CY et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013; 127: 569–574. Doi: 10.1161/CIRCULATIONAHA.112.123992Bansal N, Fan D, Hsu CY et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013; 127: 569–574. Doi: 10.1161/CIRCULATIONAHA.112.123992O’Neal WT, Tanner RM, Efird JT et al. Atrial fibrillation and incident end-stage renal disease: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Int J Cardiol 2015; 185: 219–223. Doi: 10.1016/j.ijcard.2015.03.104O’Neal WT, Tanner RM, Efird JT et al. Atrial fibrillation and incident end-stage renal disease: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Int J Cardiol 2015; 185: 219–223. Doi: 10.1016/j.ijcard.2015.03.104Bansal N, Fan D, Hsu CY et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc 2014; 3: e001303. Doi: 10.1161/JAHA.114.001303Bansal N, Fan D, Hsu CY et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc 2014; 3: e001303. Doi: 10.1161/JAHA.114.001303Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc 2012; 1: e002097. Doi: 10.1161/JAHA.112.002097Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc 2012; 1: e002097. Doi: 10.1161/JAHA.112.002097Chan PH, Huang D, Yip PS et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace 2016; 18: 665–671. Doi: 10.1093/ europace/euv289Chan PH, Huang D, Yip PS et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace 2016; 18: 665–671. Doi: 10.1093/ europace/euv289Chao TF, Liu CJ, Wang KL et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014; 11: 1752–1759. Doi: 10.1016/j.hrthm.2014.06.021Chao TF, Liu CJ, Wang KL et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014; 11: 1752–1759. Doi: 10.1016/j.hrthm.2014.06.021Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297–306. Doi: 10.1093/eurheartj/ehu139Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297–306. Doi: 10.1093/eurheartj/ehu139Roldan V, Marin F, Manzano-Fernandez S et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013; 109: 956–960. Doi: 10.1160/TH13-01-005Roldan V, Marin F, Manzano-Fernandez S et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013; 109: 956–960. Doi: 10.1160/TH13-01-005Singer DE, Chang Y, Borowsky LH et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2: e000250. Doi: 10.1161/JAHA.113.000250Singer DE, Chang Y, Borowsky LH et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2: e000250. Doi: 10.1161/JAHA.113.000250Kerr KF, Wang Z, Janes H et al. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 2014; 25: 114–121. Doi: 10.1097/EDE.0000000000000018Kerr KF, Wang Z, Janes H et al. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 2014; 25: 114–121. Doi: 10.1097/EDE.0000000000000018January CT, Wann LS, Alpert JS et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: 2246–2276. Doi: 10.1016/j.jacc.2015.09.018January CT, Wann LS, Alpert JS et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: 2246–2276. Doi: 10.1016/j.jacc.2015.09.018Bonde AN, Lip GY, Kamper AL et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64: 2471–2482. Doi: 10.1016/j.jacc.2014.09.051Bonde AN, Lip GY, Kamper AL et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64: 2471–2482. Doi: 10.1016/j.jacc.2014.09.051American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 1S–70S, e1S–e801S. Doi: 10.1378/ chest.1412S3American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 1S–70S, e1S–e801S. Doi: 10.1378/ chest.1412S3Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47: 895–900. Doi: 10.1161/STROKEAHA.115.012004Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47: 895–900. Doi: 10.1161/STROKEAHA.115.012004Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151. Doi: 10.1056/NEJMoa0905561Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151. Doi: 10.1056/NEJMoa0905561Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891. Doi: 10.1056/NEJMoa1009638Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891. Doi: 10.1056/NEJMoa1009638Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992. Doi: 10.1056/NEJMoa1107039Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992. Doi: 10.1056/NEJMoa1107039Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093–2104. Doi: 10.1056/NEJMoa1310907Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093–2104. Doi: 10.1056/NEJMoa1310907Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2599–2604. Doi: 10.2215/ CJN.02400311Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2599–2604. Doi: 10.2215/ CJN.02400311Hijazi Z, Hohnloser SH, Oldgren J et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129:961–970. Doi: 10.1161/CIRCULATIONAHA.113.003628Hijazi Z, Hohnloser SH, Oldgren J et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129:961–970. Doi: 10.1161/CIRCULATIONAHA.113.003628Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394. Doi: 10.1093/ eurheartj/ehr342Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394. Doi: 10.1093/ eurheartj/ehr342Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830. Doi: 10.1093/eurheartj/ehs274Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830. Doi: 10.1093/eurheartj/ehs274Eikelboom JW, Connolly SJ, Gao P et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012; 21:429–435. Doi: 10.1016/j.jstrokecerebrovasdis.2012.05.007Eikelboom JW, Connolly SJ, Gao P et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012; 21:429–435. Doi: 10.1016/j.jstrokecerebrovasdis.2012.05.007Bohula EA, Giugliano RP, Ruff CT et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134:24–36. Doi: 10.1161/CIRCULATIONAHA.116.022361Bohula EA, Giugliano RP, Ruff CT et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134:24–36. Doi: 10.1161/CIRCULATIONAHA.116.022361Qamar A, Bhatt DL. Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015; 11:200–202. Doi: 10.1038/nrneph.2015.14Qamar A, Bhatt DL. Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015; 11:200–202. Doi: 10.1038/nrneph.2015.14Lau YC, Proietti M, Guiducci E et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 2016; 68:1452–1464. Doi: 10.1016/j.jacc.2016.06.057Lau YC, Proietti M, Guiducci E et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 2016; 68:1452–1464. Doi: 10.1016/j.jacc.2016.06.057Tan J, Liu S, Segal JB et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016; 17:157. Doi: 10.1186/s12882-016-0368-6Tan J, Liu S, Segal JB et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016; 17:157. Doi: 10.1186/s12882-016-0368-6Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese endstage renal disease patients. Nephrol Dial Transplant 2012; 27:1580–1584. Doi: 10.1093/ndt/ gfr658Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese endstage renal disease patients. Nephrol Dial Transplant 2012; 27:1580–1584. Doi: 10.1093/ndt/ gfr658Carrero JJ, Evans M, Szummer K et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014; 311: 919–928. Doi: 10.1001/jama.2014.1334Carrero JJ, Evans M, Szummer K et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014; 311: 919–928. Doi: 10.1001/jama.2014.1334Szummer K, Gasparini A, Eliasson S et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017; 6:e004925. Doi: 10.1161/JAHA.116.004925Szummer K, Gasparini A, Eliasson S et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017; 6:e004925. Doi: 10.1161/JAHA.116.004925Yang F, Hellyer JA, Than C et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017; 103:818–826. Doi: 10.1136/ heartjnl-2016-309266Yang F, Hellyer JA, Than C et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017; 103:818–826. Doi: 10.1136/ heartjnl-2016-309266Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? Jama 2014; 311:913–915. Doi: 10.1001/jamasurg.2014.926Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? Jama 2014; 311:913–915. Doi: 10.1001/jamasurg.2014.926Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80:181–189. Doi: 10.1038/ki.2011.44Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80:181–189. Doi: 10.1038/ki.2011.44Holden RM, Booth SL. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 2007; 3:522–523. Doi: 10.1038/ncpneph0601Holden RM, Booth SL. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 2007; 3:522–523. Doi: 10.1038/ncpneph0601Kooiman J, van der Hulle T, Maas H et al. Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease. J Am Coll Cardiol 2016; 67:2442–2444. Doi: 10.1016/j.jacc.2016.03.516Kooiman J, van der Hulle T, Maas H et al. Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease. J Am Coll Cardiol 2016; 67:2442–2444. Doi: 10.1016/j.jacc.2016.03.516Dias C, Moore KT, Murphy J et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016; 43:229–236. Doi: 10.1159/000445328Dias C, Moore KT, Murphy J et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016; 43:229–236. Doi: 10.1159/000445328De Vriese AS, Caluwe R, Bailleul E et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91–98. Doi: 10.1053/j.ajkd.2015.01.022De Vriese AS, Caluwe R, Bailleul E et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91–98. Doi: 10.1053/j.ajkd.2015.01.022Wang X, Tirucherai G, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with endstage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628–636. Doi: 10.1002/jcph.628Wang X, Tirucherai G, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with endstage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628–636. Doi: 10.1002/jcph.628Mavrakanas TA, Samer CF, Nessim SJ et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 2241–2248. Doi: 10.1681/ASN.2016090980Mavrakanas TA, Samer CF, Nessim SJ et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 2241–2248. Doi: 10.1681/ASN.2016090980Matzke GR, Aronoff GR, Atkinson AJ et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122–1137. Doi: 10.1038/ ki.2011.322Matzke GR, Aronoff GR, Atkinson AJ et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122–1137. Doi: 10.1038/ ki.2011.322Manzano-Fernández S, Andreu-Cayuelas JM, Marı´n F et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2015; 68: 497–504. Doi: 10.1016/j. rec.2014.06.026Manzano-Fernández S, Andreu-Cayuelas JM, Marı´n F et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2015; 68: 497–504. Doi: 10.1016/j. rec.2014.06.026Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3 (Suppl): 1–150.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3 (Suppl): 1–150.Chan KE, Edelman ER, Wenger JB et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131: 972–979. Doi: 10.1161/CIRCULATIONAHA.114.014113.Chan KE, Edelman ER, Wenger JB et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131: 972–979. Doi: 10.1161/CIRCULATIONAHA.114.014113.Winkelmayer WC, Herzog CA, Montez-Rath ME et al. Use of novel oral anticoagulants in patients with end-stage renal disease. Hemodial Int 2015; 19: 150–153. Doi: 10.1111/hdi.12251.Winkelmayer WC, Herzog CA, Montez-Rath ME et al. Use of novel oral anticoagulants in patients with end-stage renal disease. Hemodial Int 2015; 19: 150–153. Doi: 10.1111/hdi.12251.Shroff GR. Renal function in patients with atrial fibrillation receiving anticoagulants: the canaries in the coal mine. JAMA Cardiol 2016; 1: 375–376. Doi: 10.1001/jamacardio.2016.1258.Shroff GR. Renal function in patients with atrial fibrillation receiving anticoagulants: the canaries in the coal mine. JAMA Cardiol 2016; 1: 375–376. Doi: 10.1001/jamacardio.2016.1258.Yao X, Shah ND, Sangaralingham LR et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69: 2779–2790. Doi: 10.1016/j.jacc.2017.03.600Yao X, Shah ND, Sangaralingham LR et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69: 2779–2790. Doi: 10.1016/j.jacc.2017.03.600Kirchhof P, Breithardt G, Bax J et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016; 18: 37–50. Doi: 10.1093/ europace/euv304.Kirchhof P, Breithardt G, Bax J et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016; 18: 37–50. Doi: 10.1093/ europace/euv304.Bohm M, Ezekowitz MD, Connolly SJ et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65: 2481–2493. Doi: 10.1016/j. jacc.2015.03.577Bohm M, Ezekowitz MD, Connolly SJ et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65: 2481–2493. Doi: 10.1016/j. jacc.2015.03.577Doherty JU, Gluckman TJ, Hucker WJ et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69: 871–898. Doi: 10.1016/j.jacc.2016.11.024Doherty JU, Gluckman TJ, Hucker WJ et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69: 871–898. Doi: 10.1016/j.jacc.2016.11.024Janssen MJ, Huijgens PC, Bouman AA et al. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993;8:1228–1233. Doi: -Janssen MJ, Huijgens PC, Bouman AA et al. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993;8:1228–1233. Doi: -Glund S, Stangier J, van Ryn J et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumabmediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56: 41–54. Doi: 10.1007/s40262-016-0417-0Glund S, Stangier J, van Ryn J et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumabmediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56: 41–54. Doi: 10.1007/s40262-016-0417-0Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817. Doi: 10.1056/NEJMoa1007432.Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817. Doi: 10.1056/NEJMoa1007432.Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434. Doi: 10.1056/NEJMoa1611594.Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434. Doi: 10.1056/NEJMoa1611594.Reddy VY, Doshi SK, Kar S et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70: 2964–2975. Doi: 10.1016/j. jacc.2017.10.021.Reddy VY, Doshi SK, Kar S et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70: 2964–2975. Doi: 10.1016/j. jacc.2017.10.021.Kefer J, Tzikas A, Freixa X et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016; 207: 335–340. Doi: 10.1016/j.ijcard.2016.01.003.Kefer J, Tzikas A, Freixa X et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016; 207: 335–340. Doi: 10.1016/j.ijcard.2016.01.003.Wyse DG, Waldo AL, DiMarco JP et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833. Doi: 10.1056/ NEJMoa021328Wyse DG, Waldo AL, DiMarco JP et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833. Doi: 10.1056/ NEJMoa021328Testa L, Biondi-Zoccai GG, Dello Russo A et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005; 26: 2000–2006. Doi: 10.1093/eurheartj/ehi306Testa L, Biondi-Zoccai GG, Dello Russo A et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005; 26: 2000–2006. Doi: 10.1093/eurheartj/ehi306Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013; 36: 122–133. Doi: 10.1111/j.1540-8159.2012.03513.x.Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013; 36: 122–133. Doi: 10.1111/j.1540-8159.2012.03513.x.Wyse DG. Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis 2005; 48: 125–138. Doi: 10.1016/j. pcad.2005.06.008Wyse DG. Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis 2005; 48: 125–138. Doi: 10.1016/j. pcad.2005.06.008Verde E, Perez de Prado A, Lopez-Gomez JM et al. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016; 11: 2210–2217. Doi: 10.2215/CJN.04310416Verde E, Perez de Prado A, Lopez-Gomez JM et al. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016; 11: 2210–2217. Doi: 10.2215/CJN.04310416Van Gelder IC, Groenveld HF, Crijns HJ et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363–1373. Doi: 10.1056/ NEJMoa1001337Van Gelder IC, Groenveld HF, Crijns HJ et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363–1373. Doi: 10.1056/ NEJMoa1001337Williams ES, Thompson VP, Chiswell KE et al. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. Cardiol J 2013; 20: 439–446. Doi: 10.5603/CJ.2013.0104.Williams ES, Thompson VP, Chiswell KE et al. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. Cardiol J 2013; 20: 439–446. Doi: 10.5603/CJ.2013.0104.Potpara TS, Jokic V, Dagres N et al. Cardiac arrhythmias in patients with chronic kidney disease: implications of renal failure for antiarrhythmic drug therapy. Curr Med Chem 2016; 23: 2070–2083. Doi: –Potpara TS, Jokic V, Dagres N et al. Cardiac arrhythmias in patients with chronic kidney disease: implications of renal failure for antiarrhythmic drug therapy. Curr Med Chem 2016; 23: 2070–2083. Doi: –Weir MA, Dixon SN, Fleet JL et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987–996. Doi: 10.1681/ASN.2014040324Weir MA, Dixon SN, Fleet JL et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987–996. Doi: 10.1681/ASN.2014040324Hoffmann KJ, Regardh CG, Aurell M et al. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 1980; 5: 181–191. Doi: 10.2165/00003088-198005020-00005Hoffmann KJ, Regardh CG, Aurell M et al. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 1980; 5: 181–191. Doi: 10.2165/00003088-198005020-00005https://www.drugbank.ca/drugs/DB00598 (13 February 2018).https://www.drugbank.ca/drugs/DB00598 (13 February 2018).Daheb K, Lipman ML, Hildgen P, Roy JJ. Artificial neural network modeling for drug dialyzability prediction. J Pharm Pharm Sci 2013; 16: 665–675. Doi: -Daheb K, Lipman ML, Hildgen P, Roy JJ. Artificial neural network modeling for drug dialyzability prediction. J Pharm Pharm Sci 2013; 16: 665–675. Doi: -Frishman WSD. Cardiovascular Pharmacotherapies. Minneapolis, MN: Cardiotext Publisher; 2011Frishman WSD. Cardiovascular Pharmacotherapies. Minneapolis, MN: Cardiotext Publisher; 2011Dasgupta A, Montalvo J, Medendorp S et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007; 49: 656–663. Doi: 10.1053/j. ajkd.2007.02.272Dasgupta A, Montalvo J, Medendorp S et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007; 49: 656–663. Doi: 10.1053/j. ajkd.2007.02.272Reinecke H, Nabauer M, Gerth A et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 2015; 87: 200–209. Doi: 10.1038/ki.2014.195.Reinecke H, Nabauer M, Gerth A et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 2015; 87: 200–209. Doi: 10.1038/ki.2014.195.Schmidt M, Daccarett M, Rittger H et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011; 22: 1092–1098. Doi: 10.1111/j.1540-8167.2011.02069.xSchmidt M, Daccarett M, Rittger H et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011; 22: 1092–1098. Doi: 10.1111/j.1540-8167.2011.02069.xhttps://www.drugbank.ca/drugs/DB01182 (13 February 2018).https://www.drugbank.ca/drugs/DB01182 (13 February 2018).Ullal AJ, Than CT, Fan J et al. Amiodarone and risk of death in contemporary patients with atrial fibrillation: findings from the Retrospective Evaluation and Assessment of Therapies in AF study. Am Heart J 2015; 170: 1033–1041. Doi: 10.1016/j.ahj.2015.07.023Ullal AJ, Than CT, Fan J et al. Amiodarone and risk of death in contemporary patients with atrial fibrillation: findings from the Retrospective Evaluation and Assessment of Therapies in AF study. Am Heart J 2015; 170: 1033–1041. Doi: 10.1016/j.ahj.2015.07.023Ullal AJ, Kaiser DW, Fan J et al. Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease. J Cardiovasc Electrophysiol 2017;28:39–48. Doi:10.1111/jce.13118Ullal AJ, Kaiser DW, Fan J et al. Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease. J Cardiovasc Electrophysiol 2017;28:39–48. Doi:10.1111/jce.13118Li M, Liu T, Luo D, Li G. Systematic review and metaanalysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation. Cardiol J 2014;21:89–95 Doi:10.5603/CJ.a2013.0116Li M, Liu T, Luo D, Li G. Systematic review and metaanalysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation. Cardiol J 2014;21:89–95 Doi:10.5603/CJ.a2013.0116Yanagisawa S, Inden Y, Kato H et al. Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation: a potential effect of non-pulmonary vein foci. J Cardiol 2017;69:3–10 Doi: 10.1016/j.jjcc.2016.07.008Yanagisawa S, Inden Y, Kato H et al. Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation: a potential effect of non-pulmonary vein foci. J Cardiol 2017;69:3–10 Doi: 10.1016/j.jjcc.2016.07.008Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after catheter ablation of atrial fibrillation. Circulation 2011;124:2380–2387. Doi: 10.1161/CIRCULATION-AHA.111.047266Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after catheter ablation of atrial fibrillation. Circulation 2011;124:2380–2387. Doi: 10.1161/CIRCULATION-AHA.111.047266Marrouche NF, Brachmann J, Andresen D, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–427. Doi: 10.1056/ NEJMoa1707855Marrouche NF, Brachmann J, Andresen D, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–427. Doi: 10.1056/ NEJMoa1707855Marrouche NF, Brachmann J. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol 2009; 32:987–994. Doi: 10.1111/j.1540-8159.2009.02428.xMarrouche NF, Brachmann J. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol 2009; 32:987–994. Doi: 10.1111/j.1540-8159.2009.02428.xKwon CH, Kim J, Kim MS, et al. Impact of impaired renal function on the incidence of atrial fibrillation following radiofrequency ablation of cavotricuspid isthmusdependent atrial flutter. Korean Circ J 2015;45:473–478. Doi:10.4070/kcj.2015.45.6.473Kwon CH, Kim J, Kim MS, et al. Impact of impaired renal function on the incidence of atrial fibrillation following radiofrequency ablation of cavotricuspid isthmusdependent atrial flutter. Korean Circ J 2015;45:473–478. Doi:10.4070/kcj.2015.45.6.473Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050–2060. Doi: 10.1001/ jama.2013.280521Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050–2060. Doi: 10.1001/ jama.2013.280521Lakkireddy D, Atkins D, Pillarisetti J, et al. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study. J Am Coll Cardiol 2013;61:1177–1182. Doi: 10.1016/j.jacc.2012.11.060Lakkireddy D, Atkins D, Pillarisetti J, et al. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study. J Am Coll Cardiol 2013;61:1177–1182. Doi: 10.1016/j.jacc.2012.11.060Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110:364–367. Doi: 10.1161/01.CIR.0000136587.68725.8EGami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110:364–367. Doi: 10.1161/01.CIR.0000136587.68725.8ELi L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a metaanalysis of observational studies. Europace 2014;16:1309–1314. Doi: 10.1093/europace/euu066Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a metaanalysis of observational studies. Europace 2014;16:1309–1314. Doi: 10.1093/europace/euu066Meyring-Wosten A, Zhang H, Ye X et al. Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016;11:616–625 Doi: 10.2215/CJN.08510815Meyring-Wosten A, Zhang H, Ye X et al. Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2016;11:616–625 Doi: 10.2215/CJN.08510815Unruh ML, Sanders MH, Redline S, et al. Sleep apnea in patients on conventional thrice-weekly hemodialysis: comparison with matched controls from the Sleep Heart Health Study. J Am Soc Nephrol 2006;17:3503–3509. Doi: 10.1681/ASN.2006060659Unruh ML, Sanders MH, Redline S, et al. Sleep apnea in patients on conventional thrice-weekly hemodialysis: comparison with matched controls from the Sleep Heart Health Study. J Am Soc Nephrol 2006;17:3503–3509. Doi: 10.1681/ASN.2006060659Tuohy CV, Montez-Rath ME, Turakhia M, et al. Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrol 2016;17:16. Doi: 10.1186/ s12882-016-0229-3Tuohy CV, Montez-Rath ME, Turakhia M, et al. Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrol 2016;17:16. Doi: 10.1186/ s12882-016-0229-3Charytan DM, Lewis EF, Desai AS, et al. Cause of death in patients with diabetic CKD enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2015;66:429–440. Doi: 10.1053/j.ajkd.2015.02.324Charytan DM, Lewis EF, Desai AS, et al. Cause of death in patients with diabetic CKD enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2015;66:429–440. Doi: 10.1053/j.ajkd.2015.02.324Deo R, Sotoodehnia N, Katz R, et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes 2010;3:159–164 Doi: 10.1161/CIRCOUTCOMES.109.875369Deo R, Sotoodehnia N, Katz R, et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes 2010;3:159–164 Doi: 10.1161/CIRCOUTCOMES.109.875369Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98:485–490. Doi: 10.1016/j. amjcard.2006.03.025Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98:485–490. Doi: 10.1016/j. amjcard.2006.03.025Pun PH, Smarz TR, Honeycutt EF, et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009;76:652–658 Doi: 10.1038/ki.2009.219Pun PH, Smarz TR, Honeycutt EF, et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009;76:652–658 Doi: 10.1038/ki.2009.219Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114:2766–2772. Doi: 10.1161/ CIRCULATIONAHA.106.642892Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114:2766–2772. Doi: 10.1161/ CIRCULATIONAHA.106.642892Suzuki T, Agarwal SK, Deo R, et al. Kidney function and sudden cardiac death in the community: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2016;180:46–53. Doi: 10.1016/j.ahj.2016.07.004Suzuki T, Agarwal SK, Deo R, et al. Kidney function and sudden cardiac death in the community: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2016;180:46–53. Doi: 10.1016/j.ahj.2016.07.004Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69: 2268–2273. Doi: 10.1038/sj.ki.5000446Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69: 2268–2273. Doi: 10.1038/sj.ki.5000446Chan KE, Maddux FW, Tolkoff-Rubin N, et al. EarlyChan KE, Maddux FW, Tolkoff-Rubin N, et al. Earlyoutcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol 2011;6:2642–2649. Doi: 10.2215/ CJN.03680411outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol 2011;6:2642–2649. Doi: 10.2215/ CJN.03680411Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011;80: 572–586 Doi: 10.1038/ki.2011.223Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011;80: 572–586 Doi: 10.1038/ki.2011.223Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300–307. Doi: 10.1111/j.1525-139X.2008.00455.xHerzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300–307. Doi: 10.1111/j.1525-139X.2008.00455.xRobinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 2014;85:158–165 Doi: 10.1038/ki.2013.252Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 2014;85:158–165 Doi: 10.1038/ki.2013.252Weinhandl E, Constantini E, Everson S, et al. Peer kidney care initiative 2014 report: dialysis care and outcomes in the United States. Am J Kidney Dis 2015;65:A6. Doi: 10.1053/j. ajkd.2015.03.021Weinhandl E, Constantini E, Everson S, et al. Peer kidney care initiative 2014 report: dialysis care and outcomes in the United States. Am J Kidney Dis 2015;65:A6. Doi: 10.1053/j. ajkd.2015.03.021U.S. Renal Data System, 2017 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2017. Doi: https:// Doi.org/10.1053/j.ajkd.2017.01.036U.S. Renal Data System, 2017 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2017. Doi: https:// Doi.org/10.1053/j.ajkd.2017.01.036Wetmore JB, Gilbertson DT, Liu J, Collins AJ. Improving outcomes in patients receiving dialysis: the peer kidney care initiative. Clin J Am Soc Nephrol 2016;11: 1297–1304. Doi: 10.2215/ CJN.12981215Wetmore JB, Gilbertson DT, Liu J, Collins AJ. Improving outcomes in patients receiving dialysis: the peer kidney care initiative. Clin J Am Soc Nephrol 2016;11: 1297–1304. Doi: 10.2215/ CJN.12981215Chugh SS, Reinier K, Teodorescu C et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008;51:213–228 Doi: 10.1016/j.pcad.2008.06.003Chugh SS, Reinier K, Teodorescu C et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008;51:213–228 Doi: 10.1016/j.pcad.2008.06.003Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990–1997. Doi: 10.1093/eurheartj/ehv186Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990–1997. Doi: 10.1093/eurheartj/ehv186Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352: 2581–2588. Doi: 10.1056/NEJMoa043938Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352: 2581–2588. Doi: 10.1056/NEJMoa043938Pun PH, Herzog CA, Middleton JP. Improving ascertainment of sudden cardiac death in patients with end stage renal disease. Clin J Am Soc Nephrol 2012;7: 116–122. Doi: 10.2215/ CJN.02820311Pun PH, Herzog CA, Middleton JP. Improving ascertainment of sudden cardiac death in patients with end stage renal disease. Clin J Am Soc Nephrol 2012;7: 116–122. Doi: 10.2215/ CJN.02820311Wan C, Herzog CA, Zareba W, Szymkiewicz SJ. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. Ann Noninvasive Electrocardiol 2014;19:247–257. Doi: 10.1111/anec.12119Wan C, Herzog CA, Zareba W, Szymkiewicz SJ. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. Ann Noninvasive Electrocardiol 2014;19:247–257. Doi: 10.1111/anec.12119Wong MC, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm 2015;12:2047–2055. Doi: 10.1016/j.hrthm.2015.06.033Wong MC, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm 2015;12:2047–2055. Doi: 10.1016/j.hrthm.2015.06.033Pun PH, Lehrich RW, Honeycutt EF, et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011;79:218–227. Doi: 10.1038/ki.2010.315Pun PH, Lehrich RW, Honeycutt EF, et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011;79:218–227. Doi: 10.1038/ki.2010.315Shastri S, Tangri N, Tighiouart H, et al. Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 2012;7:123–130 Doi: 10.2215/ CJN.06320611Shastri S, Tangri N, Tighiouart H, et al. Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 2012;7:123–130 Doi: 10.2215/ CJN.06320611Friedman AN, Yu Z, Tabbey R, Denski et al. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int 2013;83:1130–1135 Doi: 10.1038/ki.2013.4Friedman AN, Yu Z, Tabbey R, Denski et al. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int 2013;83:1130–1135 Doi: 10.1038/ki.2013.4Kruzan RM, Herzog CA, Wu A et al. Association of NT-proBNP and cTnI with outpatient sudden cardiac death in hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. BMC Nephrol 2016; 17:18. https://Doi. org/10.1186/s12882-016-0230-xKruzan RM, Herzog CA, Wu A et al. Association of NT-proBNP and cTnI with outpatient sudden cardiac death in hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. BMC Nephrol 2016; 17:18. https://Doi. org/10.1186/s12882-016-0230-xSandoval Y, Herzog CA, Love SA et al. Prognostic value of serial changes in high sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. Clin Chem 2016; 62: 631–638. https://Doi.org/10.1373/ clinchem.2015.251835Sandoval Y, Herzog CA, Love SA et al. Prognostic value of serial changes in high sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. Clin Chem 2016; 62: 631–638. https://Doi.org/10.1373/ clinchem.2015.251835Wang AY, Lam CW, Chan IH et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56: 210–216. https://Doi.org/10.1161/ HYPERTENSIONAHA.110.151167Wang AY, Lam CW, Chan IH et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56: 210–216. https://Doi.org/10.1161/ HYPERTENSIONAHA.110.151167Winkler K, Wanner C, Drechsler C et al. German Diabetes and Dialysis Study Investigators. Change in N-terminal-pro-B-typenatriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008;29: 2092–2099. https://Doi.org/10.1093/eurheartj/ehn278Winkler K, Wanner C, Drechsler C et al. German Diabetes and Dialysis Study Investigators. Change in N-terminal-pro-B-typenatriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008;29: 2092–2099. https://Doi.org/10.1093/eurheartj/ehn278Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia. J Am Coll Cardiol 2012;60:1993–2004. https://Doi. org/10.1016/j.jacc.2011.12.063Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia. J Am Coll Cardiol 2012;60:1993–2004. https://Doi. org/10.1016/j.jacc.2011.12.063Roberts R, Jeffrey C, Carlisle G, Brierley E. Prospective investigation of the incidence of falls, dizziness and syncope in haemodialysis patients. Int Urol Nephrol 2007;39:275–279. https:// Doi.org/10.1007/s11255-006-9088-3Roberts R, Jeffrey C, Carlisle G, Brierley E. Prospective investigation of the incidence of falls, dizziness and syncope in haemodialysis patients. Int Urol Nephrol 2007;39:275–279. https:// Doi.org/10.1007/s11255-006-9088-3Charytan DM, Patrick AR, Liu J et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011;58:409–417. https://Doi.org/10.1053/j.ajkd.2011.03.026Charytan DM, Patrick AR, Liu J et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011;58:409–417. https://Doi.org/10.1053/j.ajkd.2011.03.026Herzog CA, Li S, Weinhandl ED et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818–825. https://Doi. org/10.1111/j.1523-1755.2005.00462.xHerzog CA, Li S, Weinhandl ED et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818–825. https://Doi. org/10.1111/j.1523-1755.2005.00462.xNakhoul GN, Schold JD, Arrigain S et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol 2015;10: 1119–1127. https://Doi.org/10.2215/CJN.11121114Nakhoul GN, Schold JD, Arrigain S et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol 2015;10: 1119–1127. https://Doi.org/10.2215/CJN.11121114Mallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59: 1559–1566. https://Doi.org/10.1046/j.1523-1755.2001.0590041559.xMallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59: 1559–1566. https://Doi.org/10.1046/j.1523-1755.2001.0590041559.xSood MM, Pauly RP, Rigatto C, Komenda P. Left ventricular dysfunction in the haemodialysis population. NDT Plus 2008;1:199–205. https://Doi.org/10.1093/ndtplus/sfn074Sood MM, Pauly RP, Rigatto C, Komenda P. Left ventricular dysfunction in the haemodialysis population. NDT Plus 2008;1:199–205. https://Doi.org/10.1093/ndtplus/sfn074Pun PH, Al-Khatib SM, Han JY et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014;64:32–39. https://Doi.org/10.1053/j. ajkd.2013.12.009Pun PH, Al-Khatib SM, Han JY et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014;64:32–39. https://Doi.org/10.1053/j. ajkd.2013.12.009El-Chami MF, Levy M, Kelli HM et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol 2015;26: 900–904. https://Doi.org/10.1111/jce.12705El-Chami MF, Levy M, Kelli HM et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol 2015;26: 900–904. https://Doi.org/10.1111/jce.12705Fotheringham J, Fogarty DG, El Nahas M et al. The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients. Kidney Int 2015;88:569–575. https://Doi.org/10.1038/ki.2015.141Fotheringham J, Fogarty DG, El Nahas M et al. The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients. Kidney Int 2015;88:569–575. https://Doi.org/10.1038/ki.2015.141Brunelli SM, Du Mond C, Oestreicher N et al. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis 2017;70:21–29. https://Doi.org/10.1053/j.ajkd.2016.10.024Brunelli SM, Du Mond C, Oestreicher N et al. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis 2017;70:21–29. https://Doi.org/10.1053/j.ajkd.2016.10.024Rhee CM, Kalantar-Zadeh K. Implications of the long interdialytic gap: a problem of excess accumulation vs. excess removal? Kidney Int 2015;88:442–444. https://Doi.org/10.1038/ ki.2015.193Rhee CM, Kalantar-Zadeh K. Implications of the long interdialytic gap: a problem of excess accumulation vs. excess removal? Kidney Int 2015;88:442–444. https://Doi.org/10.1038/ ki.2015.193Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, Aguilera AI. all centers that contributed to BIIs. Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a Propensity-Matched Score Study. PLoS One 2015;10:e0127453. https://Doi.org/10.1371/journal. pone.0127453Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, Aguilera AI. all centers that contributed to BIIs. Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a Propensity-Matched Score Study. PLoS One 2015;10:e0127453. https://Doi.org/10.1371/journal. pone.0127453Pitt B, Rossignol P. Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacol Res 2017;118:2–4. https://Doi. org/10.1016/j.phrs.2016.07.032Pitt B, Rossignol P. Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacol Res 2017;118:2–4. https://Doi. org/10.1016/j.phrs.2016.07.032Lepage L, Dufour AC, Doiron et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 2015;10:2136–2142. https://Doi.org/10.2215/CJN.03640415Lepage L, Dufour AC, Doiron et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 2015;10:2136–2142. https://Doi.org/10.2215/CJN.03640415Berlyne GM, Janabi K, Shaw AB, Hocken AG. Treatment of hyperkalemia with a calcium-resin. Lancet 1966;1:169–172. https://Doi.org/10.1016/S0140-6736(66)92460-3Berlyne GM, Janabi K, Shaw AB, Hocken AG. Treatment of hyperkalemia with a calcium-resin. Lancet 1966;1:169–172. https://Doi.org/10.1016/S0140-6736(66)92460-3Weir MR, Bakris GL, Bushinsky DA et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372: 211–221 https://Doi.org/10.1056/ NEJMoa1410853Weir MR, Bakris GL, Bushinsky DA et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372: 211–221 https://Doi.org/10.1056/ NEJMoa1410853Weir MR, Bakris GL, Gross C et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int 2016;90:696–704. https://Doi.org/10.1016/j. kint.2016.04.019Weir MR, Bakris GL, Gross C et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int 2016;90:696–704. https://Doi.org/10.1016/j. kint.2016.04.019ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547–1559. https://Doi. org/10.1056/NEJMoa0801317ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547–1559. https://Doi. org/10.1056/NEJMoa0801317Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–2213. https://Doi. org/10.1056/NEJMoa1208799Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–2213. https://Doi. org/10.1056/NEJMoa1208799Fried LF, Emanuele N, Zhang JH et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903. https:// Doi.org/10.1056/NEJMoa1303154Fried LF, Emanuele N, Zhang JH et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903. https:// Doi.org/10.1056/NEJMoa1303154Quach K, Lvtvyn L, Baigent C et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2016;68:591–598. https://Doi.org/10.1053/j.ajkd.2016.04.011Quach K, Lvtvyn L, Baigent C et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2016;68:591–598. https://Doi.org/10.1053/j.ajkd.2016.04.011Weir MR, Kline I, Xie J et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014;30:1759–1768. https://Doi.org/10.1185/03007995.2014 .919907Weir MR, Kline I, Xie J et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014;30:1759–1768. https://Doi.org/10.1185/03007995.2014 .919907Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001;60: 350–357. https:// Doi.org/10.1046/j.1523-1755.2001.00806.xKarnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001;60: 350–357. https:// Doi.org/10.1046/j.1523-1755.2001.00806.xJadoul M, Thumma J, Fuller DS et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012;7:765–774. https://Doi.org/10.2215/CJN.08850811Jadoul M, Thumma J, Fuller DS et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012;7:765–774. https://Doi.org/10.2215/CJN.08850811Karaboyas A, Zee J, Brunelli SM et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2017;69:266–277. https://Doi. org/10.1053/j.ajkd.2016.09.015Karaboyas A, Zee J, Brunelli SM et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2017;69:266–277. https://Doi. org/10.1053/j.ajkd.2016.09.015Heguilen RM, Sciurano C, Bellusci AD et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant 2005;20:591–597. https://Doi.org/10.1093/ndt/gfh661Heguilen RM, Sciurano C, Bellusci AD et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant 2005;20:591–597. https://Doi.org/10.1093/ndt/gfh661Saran R, Bragg-Gresham JL, Levin NW et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222– 1228. https://Doi.org/10.1038/sj.ki.5000186Saran R, Bragg-Gresham JL, Levin NW et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222– 1228. https://Doi.org/10.1038/sj.ki.5000186Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925–1931. https://Doi.org/10.2215/ CJN.04470709Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925–1931. https://Doi.org/10.2215/ CJN.04470709Cabrera C, Brunelli SM, Rosenbaum D et al. A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients. BMC Nephrol 2015;16:113. https://Doi. org/10.1186/s12882-015-0110-9Cabrera C, Brunelli SM, Rosenbaum D et al. A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients. BMC Nephrol 2015;16:113. https://Doi. org/10.1186/s12882-015-0110-9Calkins H, Hindricks G, Cappato R et al. 2017 HRS/EHRA/ ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20:e1. https://Doi.org/10.1093/europace/eux275Calkins H, Hindricks G, Cappato R et al. 2017 HRS/EHRA/ ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20:e1. https://Doi.org/10.1093/europace/eux275

The authors declare that there are no conflicts of interest present.